GlassScriptPhysician profile
Sheryl Natalie Brown
NPI 1740437722
$2,729.14
in general payments reported to CMS, 2019-2025
28 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.68 · 2020: $18.56 · 2023: $1,169 · 2024: $1,008 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.91 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $482.82 | 2023-2025 | Veozah |
| Abbvie INC. | $387.04 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $321.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $252.27 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $244.26 | 2023-2024 | |
| Amgen INC. | $101.16 | 2023-2024 | Evenity, Prolia, Otezla |
| Exact Sciences Corporation | $76.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $72.80 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Tris Pharma INC | $64.40 | 2023-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $60.64 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $60.58 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $51.04 | 2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Bayer Healthcare Pharmaceuticals INC. | $49.83 | 2025 | |
| Millicent US INC | $49.41 | 2023-2024 | Intrarosa, Femring |
| Phathom Pharmaceuticals, INC. | $47.91 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44.52 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $41.74 | 2024-2025 | Auvelity |
| Sanofi Pasteur INC. | $41.36 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.01 | 2023-2024 | Jardiance, Tradjenta |
| Lundbeck LLC | $39.32 | 2024-2025 | Rexulti |
| Nevro Corp. | $38.67 | 2023-2024 | Senza |
| Medtronic Minimed, INC. | $38.28 | 2019 | |
| Horizon Therapeutics Plc | $34.83 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $27.05 | 2019-2023 | |
| Phadia US INC. | $16.68 | 2025 | Immunocap |
| Globus Medical, INC. | $16.03 | 2025 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.88 | 2025 | Caplyta |
| Ascensia Diabetes Care US INC. | $13.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheryl Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.